Near term catalystsFSD Pharma wants to sell their previous cannabis facility for $21M Canadian
$ELYM elium therapeutics has their PEA results due 1st half of 2022 it could be positive or negative catalyst towards FSD Pharma because FSD Also has PEA
FSD PEA needs a new indication for a phase 2 clinical trial in the works
If they can sell the cobourg facility they can use that to improve their balance sheet
Lucid Psych - their major depressive drug candidate which is psychoactive is not yet patented from what i understand
Lucid MS - is fully patented not only in USA but also in EU
Preclinical mouse models in auto immune multiple sclerosis has shown to restore the limbs of the mice.
Lucid MS needs to start IND and or phase 1 clinical trials
Thank you